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Abstract 
Introduction. Enhanced External Counter Pulsation (EECP) is a non-invasive United States Food and Drug 
Administration (FDA) approved outpatient treatment option for the complex problem of angina, a common 
symptom of coronary heart disease. A systematic review of the literature searched to assess the effect of EECP 
on the clinical profile that comprised physiological measurements, biochemical assessments, cardiac clinical 
symptoms, physical functional status, and Health-Related Quality of Life (HRQoL) in Coronary Heart Disease 
(CHD) patients.
Material and methods. Total 258 EECP research articles from the early stage of EECP development to till 
date screened. Out of 258 EECP articles, total 60 articles (53 EECP articles for clinical profile and 7 article for 
HRQoL matched the inclusion criteria and other (n = 198) articles excluded due to irrelevant to study objectives.
Results. All enrolled studies showed a significant improvement in angina pectoris and HRQoL with reduction 
of nitroglycerine use and exercise tolerance. There are several gaps in research has been found for further 
research to evaluate the EECP effectiveness on Body Mass Index (BMI), Heart Rate, Cholesterol, Triglyceride, 
High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), HbA1C, SpO2, Vo2max level with a comparative 
assessment of cardiac and non-cardiac metabolic markers including blood glucose. 
Conclusions. There is further need of multi-centric randomize controlled trial studies to evaluate the effect 
of EECP on obese, diabetic, hypertension and other metabolic disease patients and more research required for 
further modifications in EECP device to cure, prevent and treat chronic diseases by the non-invasive procedure. 
Key words: enhanced external counter pulsation, angina pectoris, health-related quality 
of life,coronary heart disease
Acta Angiol 2018; 24, 4: 105–122
Introduction
Cardiovascular disease, especially Coronary Heart 
disease (CHD) is the number one killer and foremost 
cause of deaths around the world [1]. Angina pec-
toris, the prime symptom of coronary heart disease 
ranked first among causes of mortality [2]. The current 
non-pharmacological and non-invasive therapy available 
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for chronic stable angina (a typical symptom of coronary 
heart disease) and heart failure is Enhanced External 
Counter Pulsation (EECP). EECP is USA-FDA approved 
therapy for coronary heart disease patient [3].
EECP, an electro-mechanical system is a registered 
trademark of Vasomedical, Inc, New York, USA and 
PSK (Chinese Company) is the exclusive distributor of 
Vasomedical’sdevices all over the world [4–8]. CHD 
patients usually undergo EECP treatment of 35 con-
secutive 1-hour sessions over 5–7 weeks. Treatment 
patient is continuously monitored for cardiac outputs, 
heart rate and spo2 using ECG and finger plethysmo-
gram, which are connected to the EECP device [9–11]. 
This study designed to evaluate the effect of EECP in 
Clinical profile and HRQoL in CHD patients. 
Material and methods
searching methods
A systemic review of the literature of EECP on clinical 
profile and HRQoL in coronary heart disease patients 
was search through PubMed, Medline, Vasomedical 
EECP manufacturer web-link, and Google scholar 
sources. Searching for the articles done as per the 
inclusion and exclusion criteria of the study and the 
studies summarized in Figure 1.
Inclusion criteria
EECP article of Randomized Control Trial (RCT), case 
studies, prospective and retrospective studies on clinical 
profile and HRQoL in coronary heart disease patients 
were included. 
Exclusion criteria
Heart Failure studies, Non-cardiac EECP studies with 
RCT, Case studies, Prospective and Retrospective and 
reviews of EECP papers excluded from the study.
Quality assessment
Study quality was assessed through two authors inde-
pendently. Newcastle-Ottawa scale (NOS) was used 
to assess the quality of studies. Detail of assessment is 
given in Tables 1, 2.
Figure 1. Flowchart of screened and included studies
Table 1. Newcastle-Ottawa scale in the assessment of clinical profile included studies 
study Is the 
case de-
finition 
ade-
quate? 
(one 
point)
Repre-
sentati-
veness 
 of 
cases 
(one 
point)
selec-
tion of 
controls 
(one 
point)
Defini-
tion of 
controls 
(one 
point)
As-
sessment 
of outco-
me (one 
point)
Ade-
quacy of 
cohort 
 follow-
-up (one 
point)
Was 
follow-
-up long 
enough for 
outcomes 
 to occur? 
(one point)
Comparabi-
lity of cases 
and controls 
on basis of 
design  
or analysis 
(two points)
Total 
score 
 (nine 
points)
Lawson et al. 1992 1 1 1 1 1 1 1 2 9
Sjukri et al. 1995 1 1 1 1 1 1 1 2 9
arora et al. 1999 1 1 1 1 1 1 1 2 9
Lawson et al. 2000 1 1 1 1 1 1 1 2 9
Lawson et al. 2000 1 1 1 1 1 1 1 2 9
Urano et al. 2001 1 1 1 1 1 1 1 2 9
Stys et al. 2001 1 1 1 1 1 1 1 2 9
Barsness et al. 2001 1 1 1 1 1 1 1 2 9
Springer S et al. 2001 1 1 1 1 1 1 1 2 9
lakshmi et al. 2002 1 1 1 1 1 1 1 2 9
Stys et al. 2002 1 1 1 1 1 1 1 2 9
Michaels et al. 2002 1 1 1 1 1 1 0 2 8
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study Is the 
case de-
finition 
ade-
quate? 
(one 
point)
Repre-
sentati-
veness 
 of 
cases 
(one 
point)
selec-
tion of 
controls 
(one 
point)
Defini-
tion of 
controls 
(one 
point)
As-
sessment 
of outco-
me (one 
point)
Ade-
quacy of 
cohort 
 follow-
-up (one 
point)
Was 
follow-
-up long 
enough for 
outcomes 
 to occur? 
(one point)
Comparabi-
lity of cases 
and controls 
on basis of 
design  
or analysis 
(two points)
Total 
score 
 (nine 
points)
Soran et al. 2002 1 1 1 1 1 1 1 2 9
Fitzgerald et al. 2003 1 1 1 1 1 1 1 2 9
Bonetti et al. 2003 1 1 1 1 1 1 1 2 9
schecter et al. 2003 1 1 1 1 1 1 1 2 9
Tartaglia et al. 2003 1 1 1 1 1 1 1 2 9
Werner et al. 2003 1 1 1 1 1 1 1 2 9
Lawson et al. 2003 1 1 1 1 1 1 1 2 9
Linnemeier et al. 2003 1 1 1 1 1 1 1 2 9
Linnemeier et al. 2003 1 1 1 1 1 1 1 2 9
Bagger et al. 2004 1 1 1 1 1 1 0 2 8
Michaels et al. 2004 1 1 1 1 1 1 1 2 9
Lawson et al. 2004 1 1 1 1 1 1 1 2 9
Masuda et al. 2004 1 1 1 1 1 1 1 2 9
Henrikson et al. 2004 1 1 1 1 1 1 1 2 9
Taguchi et al. 2004 1 1 1 1 1 1 1 2 9
Lawson et al. 2005 1 1 1 1 1 1 1 2 9
Michaels et al. 2005 1 1 1 1 1 1 1 2 9
arora et al. 2005 1 1 1 1 1 1 1 2 9
McCullough et al. 2006 1 1 1 1 1 1 1 2 9
Soran et al. 2006 1 1 1 1 1 1 1 2 9
akhtar et al. 2006 1 1 1 1 1 1 1 2 9
nichols et al. 2006 1 1 1 1 1 1 1 2 9
Lawson et al. 2006 1 1 1 1 1 1 1 2 9
novo et al. 2006 1 1 1 1 1 1 1 2 9
loh et al. 2006 1 1 1 1 1 1 1 2 9
arora et al. 2007 1 1 1 1 1 1 1 2 9
Michaels et al. 2007 1 1 1 1 1 1 1 2 9
McCullough et al. 2007 1 1 1 1 1 1 1 2 9
yavari et al. 2007 1 1 1 1 1 1 1 2 9
loh et al. 2008 1 1 1 1 1 1 1 2 9
Erdling et al. 2008 1 1 1 1 1 1 1 2 9
Buschmann et al. 2009 1 1 1 1 1 1 1 2 9
Esmaeilzadeh et al. 2009 1 1 1 1 1 1 1 2 9
Soran et al. 2012 1 1 1 1 1 1 1 2 9
Eslamian et al. 2013 1 1 1 1 1 1 1 2 9
Bozorgi et al. 2014 1 1 1 1 1 1 1 2 9
Beck et al. 2014 1 1 1 1 1 1 1 2 9
Tabary et al. 2015 1 1 1 1 1 1 1 2 9
Subramanian et al. 2016 1 1 1 1 1 1 0 2 8
Beck et al. 2016 1 1 1 1 1 1 1 2 9
Table 1. cont. Newcastle-Ottawa scale in the assessment of clinical profile included studies
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statistical analysis
Statistical analyses were performed using RevMan 5.0 
(Cochrane Collaboration). A random-effects model was 
used with weighted mean difference (WMD) in clinical 
profile and HRQol from pre-EECP to post-EECP. Bias 
in studies was assessed through visual inspection of the 
funnel plot as well as Begg’s and Egger’s testing. Detail 
of analysis is given in Figures 2 to 5.
EFFECT OF EECP ON CLINICAL 
PROFILE IN CORONARY HEART 
DIsEAsE PATIENTs
Lawson et al. [12] conducted a study on 18 patients 
with chronic angina treated with an improved system 
of enhanced external counter pulsation (EECP) and 
found that all patients improved in angina symptoms and 
generally decreased anti-angina medications. A decrease 
in myocardial ischemia observed in 67% patients and 
89% of patients were symptom-free. Sjukri et al. [13] 
carried out a study on 201 coronary heart disease 
patients. The results of the study showed significant 
improvement in coronary perfusion by 86.8% and ex-
ercise tolerance by 94.2%. Arora et al. [14] performed 
a multi centric prospective randomized control study 
to assess the safety and efficacy of enhanced external 
counterpulsation (EECP). A significant improvement in 
angina severity and exercise tolerance and timing was 
reported. EECP showed well tolerated and safe therapy 
for CHD patients. Lawson et al. [15] carried out a study 
on 33 patients to evaluate the effect of EECP on long-
term prognosis in CHD patients. The study suggests that 
particularly for the majority of patients demonstrating 
improvement by 64% in radionuclide stress perfusion 
post-treatment and EECP may be an effective long-term 
therapy. Lawson et al. [16] conducted a cohort study in 
2,289 CHD patients to evaluate EECP safety and efficacy. 
EECP was found to be safe and well-tolerated therapy 
with improvement in angina class by 74% with signifi-
cant p-value (p < 0.001). Urano et al. [17] performed 
a study on 512 CHD patients to examined EECP efficacy 
in myocardial ischemia, exercise tolerance and cardiac 
Table 2. Newcastle-Ottawa scale health related quality assessment of included studies
study Is the 
case de-
finition 
ade-
quate? 
(one 
point)
Repre-
sentati-
veness 
 of 
cases 
(one 
point)
selec-
tion of 
controls 
(one 
point)
Defini-
tion of 
controls 
(one 
point)
As-
sessment 
of outco-
me (one 
point)
Ade-
quacy of 
cohort 
 follow-
-up (one 
point)
Was 
follow-
-up long 
enough for 
outcomes 
 to occur? 
(one point)
Comparabi-
lity of cases 
and controls 
on basis of 
design  
or analysis 
(two points)
Total 
score 
 (nine 
points)
arora et al. 2002 1 1 1 1 1 1 1 2 9
Kumar et al. 2009 1 1 1 1 1 1 1 2 9
Wu et al. 2012 1 1 1 1 1 1 0 2 8
Ziaeirad et al. 2012 1 1 1 1 1 1 1 2 9
 Jorgensen et al. 2013 1 1 1 1 1 1 1 2 9
May et al. 2015 1 1 1 1 1 1 0 2 8
shakouri 2015 1 1 1 1 1 1 1 2 9
Figure 2. Funnel plot of included studies in clinical profile — 
eecP
Figure 3. Funnel plot of included studies in HRQoL — EECP
Funnel plot with pseudo 95% confidence limits
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Figure 4. Forest plot of weighted mean differences in clinical profile in pre- and post-EECP
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function. The result of the study reveals the improve-
ment in exercise test parameters reduced myocardial 
ischemia by thallium scintigraphy in association with 
improved LV diastolic filling in patients with stable CAD.
Stys et al. [18] carried out a clinical registry of 37 
centers with the enrollment of 395 chronic stable an-
gina patients to examine the relation of the ER to post 
treatment improvement in Canadian Cardiovascular 
Society (CCS) angina class. After EECP, CCS improved 
by at least 1 class in 88% of patients, 87% of men and 
92% of women. EECP is effective in improving CCS 
in chronic stable angina patients. Barsness et al. [19] 
performed a study on 1246 CHD patients to determine 
whether EECP is a safe and effective treatment for 
patients with angina pectoris. The results demonstrat-
ed significant improvement in angina and reduction in 
nitroglycerine anti-angina drugs by 61.7%. Springer 
et al. [20] conducted a study on 28 CHD patients to 
assess psychological function and well-being status and 
observed significant improvement in psychological and 
well-being status. Lakshmi et al. [21] carried out a study 
on 2486 patients those were enrolled in the IEPR. The 
study revealed a significant improvement in angina class 
in patients whose DA ratio was increased and results 
sustained for 6 months. Stys et al. [22] performed a 
study on 175 CHD patients and found a significant im-
provement in angina class in 85% of patients. This study 
results showed the EECP effectiveness in improving 
stress myocardial perfusion with exercise tolerance in 
CAD patients. 
Michaels et al. [23] conducted a study on 10 CHD pa-
tients and found the significant improvement in diastolic 
and mean pressures with reduction of systolic pressure 
in the central aorta and the coronary artery of CAD 
patients. The study concludes that EECP may serve as a 
potential mechanical assistant device for CAD patients. 
holubkov et al. [24] carried out a study on 771 CHD 
patients treated with EECP and the results of this study 
conclude that EECP may be a safe treatment option for 
CAD patients. Soran et al. [25] performed a study on 
1402 CHD patients and the results showed that angina 
decreased by at least one class in 67% of patients with 
LV dysfunction just after completion of EECP treatment. 
Fitzgerald et al. [26] conducted a cohort study on 4669 
CHD patients and found decreased angina episodes 
and nitroglycerin use and 74.8% reduction in Canadian 
Cardiovascular Society (CCS) functional class and im-
provement in angina sustained for 6 months. Bonetti 
et al. [27] performed a study on 23 CHD patients to 
examine the effect of enhanced external counter pulsa-
tion (EECP) on endothelial function and found that 70% 
patients get symptomatic relief by EECP treatment. 
The author revealed that significant improvement in 
endothelial function by EECP may benefit to the clinical 
status of CHD patients. 
schecter et al. [28] carried out a study of 20 CHD pa-
tients to investigate the influence of short-term external 
counterpulsation (ECP) therapy on flow-mediated 
dilation (FMD) in patients with coronary artery disease 
(CAD). The author revealed that external counter pul-
sation may improve vascular endothelial function and 
refractory angina pectoris in CHD patients. Tartaglia 
et al. [29] conducted a study on 25 CHD patients to 
determine the effect of EECP on exercise capacity and 
myocardial perfusion by comparing results of maximal 
exercise radionuclide testing pre- and post-EECP treat-
ment. A significant improvement in treadmill times has 
been reported and radionuclide perfusion scores also 
showed a significant reduction in ischemic segments. 
Werner et al. [30] performed a study on 48 CHD 
patients and weekly angina episodes were reduced by 
48%, nitroglycerin puffs were reduced by 51%, work 
capacity was improved by 22%. Study validates the 
reduction of angina with significant improvement of 
work capacity after EECP.
Lawson et al. [31] carried out a study on 4592 CHD 
patients and his collected data from international en-
hanced external counter pulsation (EECP) patient regis-
Figure 5. Forest plot of weighted mean differences in HRQoL in pre- and post-EECP
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try showed significant improvement in angina by 73% in 
at least 1 class and 2 classes by 35.2% and 3 classes by 
17.3%. The mean angina episodes per week decrease 
to 2.5 per week after EECP treatment and nitroglycer-
ine uses per week after EECP was 2.5 times per week 
and improvement in functional status also observed in 
the study. Linnemeier et al. [32] conducted a study on 
3037 CHD patients to determine whether enhanced ex-
ternal counterpulsation is a safe and effective treatment 
for angina in octogenarians. At 6-month follow-up, 81% 
of patients sustained angina improvement. This study 
concludes that enhanced external counterpulsation is 
effective and well tolerable non-invasive treatment. 
Linnemeier et al. [33] performed another study on 
1532 IEPR patients. The author demonstrated that 
after 1 year, maintenance of angina rate was reduced in 
86% of patients with diabetes. This study also suggests 
that in diabetes patients, EECP can be a safe, effective, 
well-tolerated treatment option for the relief of angina. 
Bagger et al. [34] carried out a study on 23 patients 
with angina pectoris with positive dobutamine stress 
echocardiogram. This study was done to evaluate 
EECP effectiveness on dobutamine stress-induced wall 
motion score among angina patients. The reduction in 
dobutamine-induced wall motion abnormalities after 
EECP therapy was reported. 
Michaels et al. [35] conducted the long-term outcomes 
of enhanced external counterpulsation in 1097 CHD 
patients to relieve angina and improving the quality of 
life in a large cohort of patients with chronic angina 
pectoris. 73% patients had a reduction by at least 1 
angina class at the end of treatment, and 50% report-
ed an improvement in the quality-of-life assessment 
after enhanced external counterpulsation was; these 
results were sustained at 2-year follow-up. Lawson et 
al. [36] performed a study on 2861 CHD patients to 
examine the safety and effectiveness of EECP therapy. 
Post-EECP, patients had improved their CCS angina by 
at least one class. At 6-month follow-up, the CCS-class 
improved reduction in angina episodes and nitroglycerin 
use. Enhanced external counterpulsation was proved 
an effective therapy in relieving angina in patient’s 
angina patients. Masuda et al. [37] carried out a study 
on total 18 CHD patients. Out of 18 patients, 11 were 
treated with EECP and 7 were treated 5000 IU heparin 
pretreatment along with EECP. The study was done 
to evaluate EECP and intravenous heparin injection 
therapy effectiveness in angina pectoris patients and the 
results of the study showed significant improvement in 
exercise capacity and oxygen metabolism of coronary 
heart disease patients treated with combination therapy 
of EECP and heparin. 
Henrikson et al. [38] conducted a study on 28 CHD 
patients and found that post EECP most patients (82%) 
had at least one full class improvement in their angina 
pattern. EECP remains an effective treatment for se-
vere CAD. Taguchi et al. [39] performed study on 24 
patients with myocardial infarction. This study was done 
to assess the haemodynamic effects of EECP and its 
mechanism with special reference to neurohumoral fac-
tors. The finding of this study suggests that an increase 
in ANP without an increase in BNP is an important 
mechanism for the effects of EECP therapy. Lawson et 
al. [40] carried out a study on 2007 CHD patients and 
demonstrated the angina reduction by 83% at least one 
CCS angina class and improvement in weekly angina 
episodes and their frequency of nitroglycerine use de-
creased with improvement in well-being status by 63%. 
Michaels et al. [41] conducted a study on 1192 CHD 
patients to assess the frequency, efficacy, predictors, 
and long-term success of repeat enhanced external 
counter pulsation (EECP) therapy in relieving angina in 
a large cohort of angina patients. After 2 years of EECP 
therapy,70% of patients reported the significant de-
crease in angina and nitroglycerine consumption. Arora 
et al. [42] performed a study on 30 patients with stable 
angina pectoris having class II-IV. This study was done 
to assess the effect of EECP on vascular cell release 
of coagulation factors. The author reveals that EECP 
may not play a significant role in controlling coagulation 
factors in CHD patients. 
McCullough et al. [43] carried out a study on 2730 
obese heart patients to evaluate the association of 
baseline body mass index (BMI) on the outcomes of 
enhanced external counterpulsation (EECP) therapy 
for chronic stable angina. A greater reduction in weekly 
angina episodes from baseline to follow up observed 
and study conclude that reduction of angina is directly 
proportional to BMI value. Akhtar et al. [44] conducted 
a study on 13 CHD patients to evaluate the effect of 
EECP treatment on plasma nitric oxide and endothe-
lin-1 level. This study concludes that EECP may increase 
nitric oxide and decreases endothelin-1 levels.
Soran et al. [45] carried out a cohort study on 363 CHD 
patients and post EECP treatment, there was a signif-
icant decrease in severity of angina class (p < 0.001), 
and 72% patients were improved from severe angina 
and 52% of patients discontinued nitroglycerin use. At 
2 years of follow up 55%, patients showed improve-
ment in angina and prove that EECP is effective and 
durable therapy approach for CAD patients and 52% 
CHD patients discontinued nitroglycerin use. Nichols 
et al. [46] performed a study on 20 angina patients to 
prove the hypothesis of arterial properties and wave 
reflection characteristics favourably altered after EECP. 
The study revealed that EECP treatment may reduce 
arterial stiffness and can improve wave reflection char-
acteristics in patients with angina.
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Lawson et al. [47] conducted a study on 1458 CHD pa-
tients and found that EECP significantly reduced angina 
frequency, nitroglycerin use. Significant improvements 
in angina by 70–74% with reduction of nitroglycerine 
use by 52% with better well-being persist until 2 years 
of follow up. Novo et al. [48] carried out a study on 
25 CHD patients to evaluate the efficacy of EECP on 
clinical symptoms, myocardial ischemia and cardiac 
performed in intractable angina patients. 84 per cent of 
patients showed an increment in at least one functional 
angina class and reduced inducible ischemia and max-
imal benefits observed in patients with worst systolic 
failure had been observed. 
loh et al. [49] did a study on 58 CHD patients to as-
sess EECP immediate and long-term effectiveness in 
chronic stable refractory angina patients. This study 
results showed that angina improved at least one 
class CCS angina improvement by 78% after 1 year 
and increase exercise capacity with the reduction in 
nitroglycerine use. Arora et al. [50] conducted a study 
on 11 CHD patients to assess the effect of EECP on 
myocardial perfusion. In this study no significant effect 
on myocardial perfusion seen due to very less sample 
size and highly variable clinical responses. Michaels et 
al. [51] performed a study on 27 patients and significant 
improvement in in heart rate variability in diabetic CHD 
patients and associated with reduced with reduced 
mortality rate had been reported. McCullough et al. 
[52] did a study on 902 patients from the IEPR. This 
study was done to evaluate the degree of residual angina 
on the clinical outcomes of EECP and conclude that 
residual high-grade angina pectoris occurs after post 
EECP in those patients who had the history of severe 
angina and multi-vessel disease. 
yavari et al. [53] conducted a study on 67 CHD patients 
to assess EECP efficacy in relieving angina and improving 
myocardial ischemia. The results of this study conclude 
that EECP is safe, effective and well-tolerated therapy 
for angina pectoris treatment. Loh et al. [54] did a study 
on 1477 CHD patients to evaluate EECP effectiveness. 
Immediately after EECP, angina reduction has been seen 
with p < 0.001. The improvement in CCS class was 
improved by at least 1 class in 78% of the patients and 
by at least 2 classes in 38% and sustained in 74% of the 
patients during follow-up for 3 years. Erdling et al. [55] 
carried out a study on 86 CHD patients and conclude 
that after EECP treatment 79% of patients showed 
improvement in CCS class immediately and 61.5% 
of patients sustained these benefits till 12 months and 
29% at 2 years follow up. The author concludes that 
EECP is safe & effective for CAD with angina pectoris 
patients and patients with CCS angina class III & IV 
reported maximum improvement. Buschmann et al. 
[56] conducted a study on 23 CHD patients and found 
improvement in CCS and NYHA class in CAD patients 
with significant improvement in pressure derived collat-
eral flow index and fractional flow, which also increased.
Esmaeilzadeh et al. [57] performed a study on 20 
CHD patients to assess the effects of EECP on cardiac 
functions and found a reduction in NYHA angina class. 
Significant improvement was observed in LV systolic, 
diastolic function in angina patient. Soran et al. [58] 
conducted a study on 2072 patients and treated with 
EECP. Significant reduction by 76–84% in the severity 
of angina in CAD patients at 1 year of follow up was 
reported and both US and turkey group got good 
results. Eslamian et al. [59] performed a study on 50 
CHD patients to assess Enhanced External Counter 
Pulsation (EECP) effectiveness on clinical symptoms, 
echocardiographic measurements, and perfusion scan 
parameters and exercise tolerancetest. A significant 
improvement was observed in angina severity and well-
being status. Bozorgi et al. [60] did a study on 20 CHD 
patients with refractory angina. A significant reduction 
in angina classes III and IV was reported with sustained 
results for 6 months. The author concludes that EECP 
decreased symptoms and increased total exercise time 
and sustained these results for 6 months.
Beck et al. [61] conducted a study on 24 CHD patients 
and significant improvement in plasma level of nitrates, 
improved peak VO2, and reduced LV function with 
significant improvement in peripheral vascular function 
and functional capacity had been reported. Tabary et al. 
[62] performed a study on 48 CHD patients to assess 
clinical and para-clinical effects of enhanced external 
counterpulsation (EECP) effectiveness. Significant im-
provement in hemoglobin, LVEF, diastolic and systolic 
B.P, Chest pain, dyspnea and improvement in clinical 
conditions had been reported. Subramanian et al. [63] 
did a study on 72 CHD patients and found significant 
improvement in central systolic pressure, brachial sys-
tolic pressure, aortic pulse pressure, and augmentation 
pressure and augmentation index. Beck et al. [64] 
conducted the study on 17 CHD patients. The author 
concludes that EECP may be useful as an adjuvant ther-
apy for improving functional classification and improve 
central blood pressure, aortic pulse pressure, wasted 
left ventricular energy, andmyocardial oxygen demand 
in CHD patients.
EFFECT OF EECP ON HR-QoL IN 
CORONARY HEART DIsEAsE PATIENTs
arora et al. [65] conducted a study to assess EECP 
effectiveness on HRQoL. A significant improvement in 
HRQoLwas observed at 12 months of follow up. The 
result shows improvements in HRQoL changes after 
EECP treatment. Kumar et al. [66] did a prospective 
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study and found that EECP significantly improved angina 
symptoms, dyspnea on exertion, and quality of life after 
35 days of treatment and at1 year follow up. EECP also 
improved the 6-minute walking capacity. Wu et al. [67] 
performed a study to evaluate EECP after six months 
regarding physical capacity and HRQoL in patients with 
refractory AP. Patients enhanced walking distance on av-
erage by 29 m after EECP. CCS class also improved and 
persisted at six months follow-up. HRQoL improved 
significantly and the effects maintained at follow-up 
after the treatment.
Ziaeirad et al. [68] did a quasi-experimental study on 
64 patients to evaluate the QoL of patients with an-
gina pectoris after treatment with enhanced external 
counterpulsation. The author reveals that EECP is an 
effective noninvasive method in treating patients with 
angina pectoris and in developing their HRQoL. Jor-
gensen et al. [69] conducted a special case study of the 
43-year-old woman who had 15 hospital admissions in 
six years due to angina. The case study proves the EECP 
effectiveness towards angina recovery and significant 
improvement in HRQoL. May et al. [70] performed a 
study to assess the effect of EECP on QoL and exercise 
capacity in CAD patients. Author of this concludes that 
quality of life and exercise capacity was improved after 
eecP. shakouri et al. [71] conducted a study to inves-
tigate the effect of EECP on plasma nitric oxide (NO) 
and HRQoL in CAD patients. The author revealed that 
HRQoLand NO level increased after EECP treatment in 
CHD patients.Summary of studies given in Tables 3, 4.
Table 3. EECP effectiveness on clinical profile in coronary heart disease patients
Author study 
(year)
Title of study sample 
size
Findings & conclusion
Lawson et al. [12] 1992 Efficacy of enhanced external 
counterpulsation in the treat-
ment of angina pectoris
18 Myocardial ischemia 67% decrease, exercise 
duration increased, reduction in anti-anginal 
medicines and 89% patients were symptom-free
Sjukri et al. [13] 1995 EECP in the treatment and reha-
bilitation of coronary patients in 
Indonesia
201 Exercise tolerance 94.2%, improvement in CCS 
angina class
arora et al. [14] 1999 The multicenter study of enhan-
ced external counterpulsation 
(MUST-EECP): effect of EECP 
on exercise-induced myocardial 
ischemia and anginal episodes
139 Exercise duration increase, angina severity 
reduced, extends times to exercise-induced 
ischemia, Nitroglycerine usage decrease
Lawson et al. [15] 2000 Long-term prognosis of patients 
with angina treated with enhan-
ced external counterpulsation: 
five-year follow-up study
33 Improvement in stress perfusion after EECP, 
64% did not suffer any major adverse cardiova-
scular event due to the effect of EECP at 5 year 
of study follow up
Lawson et al. [16] 2000 Treatment benefit in the enhan-
ced external counterpulsation 
consortium
2289 74% angina pectoris patients improved in CCS 
angina class III & IV with significant p-value 
( p< 0.001)
Urano et al. [17] 2001 Enhanced external counterpul-
sation improves exercise tole-
rance, reduces exercise-induced 
myocardial ischemia, and impro-
ves left ventricular diastolic filling 
in patients with coronary artery 
disease
512 Improvement in Exercise duration and toleran-
ce with improvement in LV function.
Improvement in diastolic filling and diastolic 
function
Stys et al. [18] 2001 Acute hemodynamic effects 
and angina improvement with 
enhanced external counterpul-
sation
395 CCS angina class improvement by at least 1 
class in 88% of patients
Barsness et al. [19] 2001 The International EECP Pa-
tient Registry (IEPR): design, 
methods, baseline characteri-
stics and acute results
1246 Decrease in at least 1 anginal class by 81% and 
mean change decrease in anginal episodes per 
week (6.4 ± 12.6) with reduction of nitrogly-
cerine use by 61.7%
Springer et al. [20] 2001 Psychosocial effects of EECP in 
the angina patient: A second 
study
28 Improvement in physical functioning and mental 
health with special reference to stress and QoL
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Findings & conclusion
lakshmi et al. [21] 2002 Relation of the Pattern of Dia-
stolic Augmentation During a 
Course of Enhanced External 
Counterpulsation (EECP) to 
Clinical Benefit (from the Inter-
national EECP Patient Registry 
[IEPR])
2486 At 6 months of follow up, the patients showed 
a higher reduction in angina class who had the 
greatest increase in the DA ratio as compared 
to those who had a decrease in the DA ratio
Stys et al. [22] 2002 Effects of enhanced external 
counterpulsation on stress ra-
dionuclide coronary perfusion 
and exercise capacity in chronic 
stable angina pectoris
175 85% angina improvement , improvement in 
stress myocardial perfusion and maximize exer-
cise functions
Michaels et al. [23] 2002 Left ventricular systolic unlo-
ading and augmentation of intra-
coronary pressure and Doppler 
flow during enhanced external 
counterpulsation
10 Diastolic BP increase, Systolic B.P decrease 
and increment in coronary flow by 28% during 
EECP treatment
holubkov et al. [24] 2002 Comparison of patients under-
going enhanced external coun-
terpulsation and percutaneous 
coronary intervention for stable 
angina pectoris
771 Angina improvement in CCS class higher who 
received EECP therapy as compared to PCI 
group
Soran et al. [25] 2002 Enhanced external counterpul-
sationas treatment for chronic 
angina in patients with left ven-
tricular dysfunction: a report 
from the International EECP 
Patient Registry (IEPR)
1402 Improvement in angina at least one class in 
67%of patients with LV dysfunction 70.6% after 
6 months of follow up
Fitzgerald et al. [26] 2003 Enhanced external counterpul-
sation as initial revascularization 
treatment for angina refractory 
to medical therapy
4,669 The decrease in anginal episode per week with 
significant value p < 0.001, reduced nitrogly-
cerine uses and CCS angina class reduction 
in 74.8 patients 
Bonetti et al. [27] 2003 Enhanced external counter-
pulsation improves endothelial 
function in patients with symp-
tomatic caD
23 Enhanced peripheral endothelial function imme-
diately after EECP treatment with a contribu-
tion to the clinical benefit of EECP 
schecter et al. [28] 2003 External counterpulsation thera-
py improves endothelial function 
in patients with refractory angina 
pectoris
20 Significant improvement in angina class 
(p < 0.001), nitrate consumption decrease 
(p < 0.001) with improvement in endothelial 
functions
Tartaglia et al. [29] 2003 Exercise capability and myocar-
dial perfusion in chronic angina 
patients treated with enhanced 
external counterpulsation
25 96% patients improved by at least one functio-
nal angina class and exercise duration increased 
in treadmill exercise testing and reduction in 
ischemic segments
Werner et al. [30] 2003 Practicability and limitations of 
enhanced external counterpul-
sation as an additional treatment 
for angina
48 Anginal episode reduced by 48%, Nitrogly-
cerine reduction by 51% and work capacity 
increase by 22%
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Findings & conclusion
Lawson et al. [31] 2003 Analysis of baseline factors 
associated with a reduction in 
chest pain in patients with angina 
pectoris treated by enhanced 
external counterpulsation
4592 Significant improvement in angina by 73% in at 
least 1 class and 2 classes by 35.2% and 3 clas-
ses by 17.3%. Mean angina episodes per week 
decrease to 2.5 per week after EECP treatment 
and nitroglycerine uses per week after EECP 
was 2.5 times per week and improvement in 
functional status also observed 
Linnemeier et al. [32] 2003 Enhanced external counterpul-
sation in the management of 
angina in the elderly
3037 Angina improvement in 81% at 6 months with 
a reduction in nitroglycerine use and improve-
ment in well-being status with decrease rate of 
cardiac hospitalization has been observed
Linnemeier et al. [33] 2003 Enhanced External Counterpul-
sation for the relief of angina in 
patients with diabetes: safety, 
efficacy and 1- year clinical 
outcomes
1532 Significant improvement in CCS angina class 
by 69% in diabetes mellitus immediately after 
EECP and 86% at 1 year follow up, reduction 
in nitroglycerine use and improvement in well-
-being status has been observed and confirm 
that EECP is safe, effective and well tolerable 
treatment
Bagger et al. [34] 2004 Effect of enhanced external co-
unterpulsation on dobutamine-
-induced left ventricular wall 
motion abnormalities in severe 
chronic angina pectoris
23 Reduction in dobutamine-induced wall motion 
abnormalities observed after EECP treatment 
Michaels et al. [35] 2004 Two-year outcomes after enhan-
ced external counterpulsation 
for stable angina pectoris (from 
the International EECP patient 
registry [IEPR]) 
1097 Significant improvement by 73% angina impro-
vement , 50% improvement in well-being of 
CAD patients at 2 years of follow up
Lawson et al. [36] 2004 The effectiveness of enhanced 
external counterpulsation in 
patients with left main disease 
and angina.
2861 Significant improvement in angina pectoris and 
reduction in nitroglycerine use and reduction in 
weekly angina episodes observed 
Masuda et al. [37] 2004 Improvement of oxygen meta-
bolism in ischemic myocardium 
as a result of enhanced external 
counterpulsation with heparin 
pretreatment for patients with 
stable angina
18 Significant improvement in exercise capacity and 
oxygen metabolism of CHD patients treated 
with EECP and intravenous heparin infusion 
combined therapy was observed
Henrikson et al. 
[38]
2004 Enhanced external counterpul-
sation therapy: significant clinical  
improvement without electrop-
hysiologic remodelling
28 Significant improvement in angina by 82% and 
effective treatment for CAD patients
Taguchi et al. [39] 2004 Effects of enhanced external 
counterpulsation on hemodyna-
mics and its mechanism relation 
to neurohumoral factors
24 Study concludes that increments in ANP wit-
hout enhancement in BNP was an important 
mechanism for EECP effectiveness 
Lawson et al. [40] 2005 Predictors of benefit in an-
gina patients one year after 
completing enhanced external 
counterpulsation: initial respon-
ders to treatment versus non 
responders
2,007 Angina reduced by at least 83% immediately, 
and improvement in weekly anginal episodes, 
the frequency of nitroglycerine use decreased 
and well-being status improved by 63% 
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Michaels et al. [41] 2005 Frequency and efficacy of repeat 
enhanced external counterpul-
sation for stable angina pectoris 
(from the International EECP 
Patient Registry)
1192 After EECP treatment 86% reported decrease 
in angina CCS class by at least one and 57% pa-
tients discontinued nitroglycerine use
After 2 years 70% patients reported significant 
decrease in angina and nitroglycerine consumption
arora et al. [42] 2005 Effects of enhanced counterpul-
sation on vascular cell release of 
coagulation factors
30 The study suggests that EECP may not play a 
vital role in controlling coagulation factors in co-
ronary heart disease patients, further research 
required 
McCullough et al. [43] 2006 Impact of body mass index on 
outcomes of enhanced external 
counterpulsation therapy
2730 Changes in angina and duke activity status have 
been observed in all BMI patients. Greater re-
duction of angina is directly proportional to BMI 
value 
Soran et al. [44] 2006 Two-year outcomes after enhan-
ced external counterpulsation 
(EECP) therapy in patients 
with refractory angina pectoris 
and left ventricular dysfunction 
(report from the International 
EECP Patient Registry) 
363 At 2 years of follow up 55% of patients showed 
improvement in angina and prove that EECP is 
effective and durable therapy approach for CAD 
patients and 52% CHD patients discontinued 
nitroglycerin use 
akhtar et al. [45] 2006 Effect of external counterpulsa-
tion on plasma nitric oxide and 
endothelin-1 levels
13 EECP increases nitric oxide and decreases 
endothelial-1 level and changes sustained 
for 3 months in CHD patients
nichols et al. [46] 2006 Enhanced external counterpulsa-
tion treatment improves arterial 
wall properties and wave reflec-
tion characteristics in patients 
with refractory angina
20 The study suggests that EECP can reduce 
arterial stiffness and may improve wave reflec-
tion characteristics in CHD patients and these 
changes decrease left ventricular afterload, my-
ocardial oxygen demand and can reduce anginal 
episodes
Lawson et al. [47] 2006 Two-year outcomes in patients 
with mild refractory angina 
treated with enhanced external 
counterpulsation
1458 Improvement in angina by 70–74% with re-
duction of nitroglycerine use by 52% with bet-
ter well-being persist till 2 years of follow up
novo et al. [48] 2006 Enhanced external counterpulsa-
tion for treatment of refractory 
angina pectoris
25 Significant improvement in angina by 84% and 
reduced inducible ischemia and maximal bene-
fits observed in patients with the worst systolic 
failure
loh et al. [49] 2006 The immediate and long-term 
outcome of enhanced external 
counterpulsation in treatment of 
chronic stable refractory angina
58 At least one class CCS angina improvement by 
78% after 1 year and increase exercise capacity 
with a reduction in nitroglycerine use
arora et al. [50] 2007 Effect of enhanced external 
counterpulsation on myocardial 
perfusion in patients with stable 
angina: A multicenter radionuc-
lide study
11 No significant effect on myocardial perfusion 
has been observed due to very less number of 
sample size and highly variable clinical responses 
and study suggest for further research to assess 
EECP effectiveness on myocardial perfusion 
Michaels et al. [51] 2007 The effects of enhanced external 
counterpulsation on time- and 
frequency-domain measures of 
heart rate variability 
27 Improvement in heart rate variability in diabetic 
CHD patients and associated with reduced with 
reduced mortality rate
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McCullough [52] 2007 Residual high-grade angina after 
enhanced external counterpulsa-
tion therapy
902 The researcher observed high residual grade 
angina after EECP in those patients who had 
severe angina and multivessel diseases
yavari et al. [53] 2007 Effects of enhanced external 
counterpulsation on anginal 
symptoms and improvements in 
objective measures of myocardial 
ischaemia
67 The study concludes that EECP is a safe, well 
tolerated and effective non-invasive therapy for 
CHD patients 
loh et al. [54] 2008 Enhanced external counter-
pulsation in the treatment of 
chronic refractory angina: a 
long-term follow-up outcome 
from the International Enhanced 
External Counterpulsation Pa-
tient Registry
1477 After 1-year EECP treatment 78% patients re-
ported reduction in CCS angina class and 74% 
of patients sustained improvement at 3-years 
follow
Erdling et al. [55] 2008 Enhanced external counter pul-
sation in treatment of refractory 
angina pectoris: two-year outco-
me and baseline factors associa-
ted with treatment failure
86 After EECP treatment 79% of patients showed 
improvement in CCS class immediately and 
61.5% of patients sustained these benefits till 12 
months and 29% at 2 years follow up and study 
conclude that EECP is safe & effective for CAD 
with angina pectoris patients and patients with 
CCS angina class III & IV reported maximum 
improvement
Buschmann et al. [56] 2009 Improvement of fractional flow 
reserve and collateral flow by 
treatment with external coun-
terpulsation.
23 Improvement in CCS and NYHA class in CAD 
patients with significant improvement in pres-
sure derived collateral flow index and fractional 
flow also increased
Esmaeilzadeh et 
al. [57]
2009 Evaluation of left ventricular 
systolic and diastolic regional 
function after enhanced external 
counter pulsation therapy using 
strain rate imaging
20 Reduction in NYHA angina class & improvement 
in LV systolic and diastolic function in patients 
with chronic angina with increment in LVEF 
from 40.25–46.25% with significant p-value 
(p < 0.001) 
Soran et al. [58] 2012 Comparison of long-term clinical 
outcomes, event-free survival 
rates of patients undergoing 
enhanced external counterpulsa-
tion for coronary artery disease 
in the united states and turkey
2072 Significant reduction in the severity of angina in 
CAD patients at 1-year of follow up
Eslamian et al. [59] 2013 Therapeutic effects of enhan-
ced external counterpulsation 
on clinical sumptoms, echo-
cardiographic measurements, 
perfusion scan parameters and 
exercise tolerance test in CAD 
patients with refractory angina
50 Significant improvement in angina severity 
(p < 0.001), wellbeing status and ischemia 
severity (p = 0.044) and demonstrated useful 
safe and effective treatment method for angina 
pectoris in CHD patients
Bozorgi et al. [60] 2014 Effect of enhanced external co-
unterpulsation (EECP) on exerci-
se time duration and 
functional capacity in patients 
with refractory angina pectoris
20 Significant reduction in the severity of angina 
and physical functioning sustained for 6 months
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Beck et al. [61] 2014 Enhanced external counter-
pulsation improves endothelial 
function and exercise capacity in 
patients with ischaemic left ven-
tricular dysfunction
24 Significant improvement in plasma level of nitra-
tes and improved peak VO2 and reduce LV fun-
ction with significant improvement in peripheral 
vascular function and functional capacity
Tabary et al. [62] 2015 The assessment of the clinical 
and paraclinical effects of enhan-
ced external counter pulsation 
therapy in patients with corona-
ry artery disease
48 Improvement in Hemoglobin, LVEF, Diastolic 
and systolic B.P, Chest pain, dyspnea and impro-
ve clinical conditions
 Subramanian et 
al. [63]
2016 Effect of enhanced external 
counter pulsation treatment on 
aortic blood pressure, arterial 
stiffness and ejection fraction in 
patients with coronary artery 
disease
72 Central B.P significantly decrease with improve-
ment in LV function in CAD patients
Beck et al. [64] 2016 Enhanced external counter pul-
sation reduces indices of central 
blood pressure and myocardial 
oxygen demand in patients with 
left ventricular dysfunction
17 EECP worked as adjuvant therapy and impro-
vement in functional status, central B.P and my-
ocardial oxygen demand in CAD patients
Table 4. EECP effectiveness on health-related the fuality of life in coronary heart disease patients
Author study 
(year)
Title of study sample 
size
Findings & conclusion
arora et al. [65] 2002 Effects of enhanced external 
counterpulsation on health-
-related quality of life continue 
12 months after treatment: a 
substudy of the multicenter 
study of enhanced external co-
unterpulsation
139 Significant improvement in Health-related QoL 
in patients who had active EECP as compare to 
those having inactive EECP in all HR-QoL para-
meters (p < 0.05)
Kumar et al. [66] 2009 Effect of enhanced external co-
unterpulsation on clinical symp-
toms, quality of life, 6-minute 
walking distance, and echocar-
diographic measurements of left 
ventricular systolic and diastolic 
function after 35 days of treat-
ment and at 1-year follow up in 
47 patients with chronic refrac-
tory angina pectoris
47 Significant improvement in QoL and walking 
capacity
Wu et al. [67] 2012 Enhanced external counterpul-
sation in patients with refractory 
angina pectoris: a pilot study 
with six months follow-up re-
garding physical capacity and 
health-related quality of life
34 Improvement in physical and functional capacity 
with HR-QoL improvement
Ziaeirad et al. [68] 2012 The effects of enhanced external 
counterpulsation on health-
-related quality of life in patients 
with angina pectoris 
64 Angina & QoL improvement
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Discussion
Above discussed EECP studies validates the significant 
improvement in CCS and NYHA angina classification, 
angina episodes, left ventricle ejection fraction func-
tioning, exercise tolerance and HRQoL with reduc-
tion of nitroglycerine use & decrease hospitalization 
rate in coronary heart disease patients. EECP used 
for angina and heart failure for the past two decades, 
but still, more research required filling the gaps in 
research. There are very few or rare study conduct-
ed to assess EECP effectiveness on BMI, Heart Rate, 
Cholesterol, Triglyceride, High-Density Lipoprotein 
(HDL), Low-Density Lipoprotein (LDL), HbA1C, SpO2, 
Vo2max, 12-minute walk or run test and comparative 
prospective randomized trials on cardiac and non-car-
diac metabolic markers. 
Conclusion
Further clinical research is required to evaluate EECP 
effectiveness on obese, diabetic, hypertension and 
other metabolic disease patients with CHD and mul-
ti-centric randomized controlled trials are required for 
further modifications in EECP device to cure, prevent, 
and treat chronic diseases such as obesity, hypertension, 
diabetes, and neurological disorders by the non-invasive 
procedure. 
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